Latest Paliperidone Stories
A study in this week's PLoS Medicine suggests that the apparent clinical effectiveness of the newer form of drugs used to treat schizophrenia and other psychotic illnesses (second-generation anti-psychotic drugs) may be enhanced by the selective reporting of trials of these drugs in medical journals – a phenomenon called publication bias.
If you’re in pain, there’s a pill for that! But it may not always be good. A new study shows clinical effectiveness of the newer form of drugs used to treat schizophrenia and other psychotic illnesses may be enhanced by a phenomenon called publication bias.
A review of previous studies suggests that even though atypical antipsychotic medications are commonly used for off-label conditions such as behavioral symptoms of dementia, anxiety, and obsessive-compulsive disorder, these medications are effective for only a few off-label conditions, and that the benefits and harms of these medications for these uses vary.
TITUSVILLE, N.J., April 11, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) on April 6 approved INVEGAÂ® (paliperidone) extended-release tablets for the treatment of schizophrenia in adolescents 12 to 17 years of age.
BEERSE, Belgium, April 4, 2011 /PRNewswire/ -- Janssen EMEA -- New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry (EPA 2011) shows treatment with RisperdalÂ® ConstaÂ® (risperidone long-acting injection (RLAI)) is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period.
ORLANDO, Fla., Nov. 19, 2010 /PRNewswire/ -- Schizophrenia is a chronic and disabling brain disorder that affects 1 percent of the U.S. population and results in substantial medical and societal costs, in particular from use of health-care resources.
HAMILTON, N.J., Sept. 14 /PRNewswire/ -- MedAvante, Inc., the leader in centralized expert evaluation of CNS disorders, announced today that the U.S.
WALTHAM, Mass., Aug.
TITUSVILLE, N.J., May 21 /PRNewswire/ -- New data on INVEGAÂ® SUSTENNAÂ® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDALÂ® CONSTAÂ® (risperidone long-acting therapy), also an injectable medicine to treat schizophrenia, will be presented next week at a major psychiatry meeting in New Orleans.
- A gift; a largess; a gratuity; a present; a dole.